Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

PURPOSE: Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Rudin, Charles M., Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Ebiana, Victoria, Pietanza, M. Catherine, Kim, Hye Ryun
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7474472/
https://ncbi.nlm.nih.gov/pubmed/32468956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados